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Dysregulation of cytokines is among the main abnormalities in Systemic Lupus Erythematosus (SLE). However, although,
estrogens, which are known to be involved in lupus disease, inﬂuence cytokine production, the underlying molecular mechanisms
remainpoorlydeﬁned.Recentevidencedemonstratesthepresenceofestrogenreceptorinvariouscelltypesoftheimmunesystem,
whiledivergenteﬀectsofestrogensonthecytokineregulationarethoughttobeimplicated.Inthispaper,weprovideanoverviewof
the current knowledge as to how estrogen-induced modulation of cytokine production in SLE is mediated by the estrogen receptor
while simultaneously clarifying various aspects of estrogen receptor signaling in this disease. The estrogen receptor subtypes, their
structure,andthemodeofactionofestrogensbygeneactivationandviaextranucleareﬀectsarebrieﬂypresented.Resultsregarding
the possible correlation between estrogen receptor gene polymorphisms and quantitative changes in the receptor protein to SLE
pathology and cytokine production are reviewed.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease of unknown origin that aﬀects several organ
systems; diverse immunological abnormalities that are asso-
ciated with this disease have been recognized both in human
and in animal models with the most consistent being: (1)
loss of B cell tolerance, (2) abnormal interactions between T
and Bcellsignaling, (3) T, Bcelland monocyte hyperactivity,
(4) production of a wide range of pathogenic autoantibodies
resulting from polyclonal B cell activation, and (5) defective
clearance of autoantigens and immune complexes [1–3].
ThekeycomponentsoftheimmunesystemsuchasBand
T lymphocytes, dendritic/macrophage cells, monocytes and
thymus are involved in the underlying mechanisms of SLE,
while an imbalance between Th-1 and Th-2 cytokine pro-
duction plays a key role in the induction and development
of the disease [4, 5]. In particular, a switch from a type 1
(Th-1) to a type 2 (Th-2) T helper has been demonstrated
where serum levels of Th-2 cytokines, such as interleukin IL-
4, IL-6, and IL-10, are elevated, while there is an observed
decreasein production ofTh-1 cytokines, including IL-2and
interferon IFN-γ [6, 7]. Among these cytokines, IL-10 seems
to play a central role in the pathogenesis of SLE as well as in
disease ﬂare induction [8–10], while IL-6 has been identiﬁed
as being a potent contributor to the diﬀerentiation of Th-
0 to Th-2 cells [11], its production increasing in patients
with active disease [12]. Moreover, the elevation of TNF-a
in the serum of SLE patients has been suggested as playing a
role in the pathogenesis of the disease [13–15]. It is therefore
apparentthatsolublemediatorsofimmuneresponsessuchas
cytokinesremainprimecandidatesforthepathogenicfactors
responsible for this systemic disease.
Although SLE still remains of unknown origin, a strong
genetic predisposition has been recognized, this often being
accompanied by environmental and hormonal factors that
contribute to the expression of the disease. Among the above
risk factors, female gender is considered to be the greatest
[16]. The observed high female prevalence is most marked
after puberty: while the pre-puberty female to male ratio is
3:1, this increases to 10:1 during the childbearing years and
decreases again to 8:1 after menopause.2 Journal of Biomedicine and Biotechnology
Although estrogens have been proposed as obvious can-
didatestoexplainthissexualdimorphism[17],measurement
of plasma estradiol levels did not reveal signiﬁcant diﬀer-
ences between normal women and women with SLE; never-
theless, abnormal levels of estrogenic metabolites have been
identiﬁed in the latter. These metabolites include 2-hydroxy-
and 16-hydroxyestrone and their derivatives produced by
theenzymaticoxidation ofestrogen.Additionally,pregnancy
is frequently associated with ﬂares of the disease in SLE
patients [17]. Of note, pregnancy can disturb the balance in
favor of the highly feminizing 16-hydroxy metabolites, thus
predisposing to SLE, while exercise or consuming speciﬁc
foods that inhibit the 16α-hydroxylase can have opposite
eﬀects [18]. The alternative metabolic pathway—the 2-
hydroxylation pathway—that leads to catechol estrogens has
been found to be suppressed in SLE patients [19]. Admin-
istration of 17-beta estradiol (E2) has also been observed to
aggravate the disease in New Zealand brown/New Zealand
white F1 female mice (a model of SLE) [20]. Interestingly,
in lupus animal models, despite the elevated estrogen 2-
hydroxylase activity, abnormal formation of 2-hydroxylated
and 16α-hydroxylated products have not been demonstrated
[21]. Moreover, Klienefelter syndrome, a XXY genetic syn-
drome characterized by an abnormal estrogen/androgen
pattern resembling the female pattern, is associated with
higher prevalence of SLE among men [22]. Concerning the
role of hormone replacement therapy and oral contraceptive
pillsintheriskofdevelopingand/orexacerbationofSLE,this
issue still remains controversial [23–28]. It is of interest to
note that, while studies in women using oral contraceptives
versus those not using oral contraceptives demonstrated no
signiﬁcantly increased risk of developing SLE, by contrast,
hormone replacement therapy in postmenopausal women
seems to increase this risk [29]. Oral contraceptive use
was not associated with changes in the disease course in
premenopausal women with SLE, at least in the nonactive
phase, but hormone replacement therapy increased the risk
of mild ﬂares in postmenopausal patients [30].
2. MolecularMechanismsof EstrogenAction
2.1. Nuclear Actions. Estrogens exert their eﬀects by activat-
ing their intracellular receptors, the estrogen receptor alpha
(ERα) and beta (ERβ) isoform, encoded by their respective
genes ESR1 and ESR2 [31, 32]. These receptor proteins
belong to the steroid receptor superfamily [33] and possess
diﬀerent sizes. Whereas ERαiscomprisedof595aminoacids,
ERβ is comprised of 530 (today known as ERβ1l o n g ) .I t
should be pointed out that the original human ERβ clone
encoded a protein of 485 aminoacids (today known as ERβ1
short). The ERβ1 long form is currently regarded as the full-
length wild type ERβ [34]. Their aminoacid sequences are
organized as follows: the ligand binding domain located in
the carboxyterminal region of the molecules, necessary for
ligand binding; the DNA-binding domain, responsible for
binding to speciﬁc DNA sequences (the Estrogen Response
Elements, EREs); and the transcriptional regulation domain
(AF-1), which is highly immunoreactive and is located in the
aminoterminal part of the molecules. ERα and ERβ exhibit
high homology in their DNA binding domain (96%), low
homology(30%)intheirAF-1domainandpartialhomology
(53%) in their ligand binding domain. Various ERα and
ERβ isoforms and splicing variants (hERβ1 long, hERβ1
short, hERβ2, hERβ4, hERβ5, hERα-46) have been described
[34, 35]. ERα and ERβ mediate their eﬀects via regulation
of transcription of target genes, directly or indirectly, ligand-
dependently or ligand-independently. Hereinafter, the term
ER refers to both ERα and ERβ subtypes.
Intheabsenceofhormone,ERisboundtoamultiprotein
complex, including heat shock proteins, which render the
receptor inactive. The ligand binding (endogenous estro-
gens or exogenous synthetic estrogen analogs) induces a
conformational change to the receptor, which results in
the release of bound accessory proteins, and promotes
homodimerization of ER subtypes (ERα and ERβ may
homodimerize or heterodimerize) and high aﬃnity binding
to consensus EREs (AGGTCAnnnTGACCT) [36]l o c a t e d
within the regulatory region of target genes [37].
The DNA bound receptors interact with many other
coactivator proteins and negative coregulators/corepressors,
resulting in the stabilization of a transcription preinitiation
complex and the remodeling of chromatin and initiation
of transcription by the basal transcriptional machinery and
RNA polymerase [38–40]. Histone acetyltransferases (HATs)
and histone deacetylases (HDACs) are key elements for the
chromatin decompaction and initiation, such activities usu-
ally possessed by coactivator/corepressor protein complexes
[39, 41, 42]. ERα and ERβ may regulate gene transcription
not only via direct binding to their consensus EREs but also
by their interaction with other transcription factors such as
the AP-1 (via protein-protein interactions) and modulation
of the binding of AP-1 to AP-1 binding sites onto DNA
(AP-1 responsive elements), thus regulating AP-1 depending
gene transcription [43]. ERα and ERβ respond diﬀerently to
certain ligands in stimulating the ERE or AP-1 pathway [44].
For example, tamoxifen is a strong agonist of AP-1 depen-
dent transcription in certain tissues (uterus, endometrium),
promoting growth, while it acts as an antiestrogen via
the classical EREs, in breast cancer tissue [45]. Similarly,
estrogen receptor may interact with NF-κB( v i ap r o t e i n -
protein interactions), resulting in modulation of the binding
of NF-κBt oN F - κB binding sites on the DNA (NF-κB
response elements), thus regulating NF-κB dependent gene
transcription. The estrogen receptor regulates NF-κB medi-
ated gene expression in a cell-type-speciﬁc manner and has
important implications in inﬂammatory processes [46, 47].
Extracellular signals such as insulin, IGF-1, EGF, and
TGF-β, phosphorylate ERα and ERβ (in the AF-1 region)
via the mitogen activated protein kinases (MAPKs) in
the absence of ligand, resulting in transactivation of the
receptors and initiation of ERE-mediated gene expression
[48]. Phosphorylation is a posttranslational modiﬁcation of
ERs on serine and tyrosine residues. Cellular enzymes such
askinasesandphosphatasestransferaphosphategroupfrom
ATP onto target proteins orremove it, respectively. Estrogens
as well as extracellular signals and regulators of the general
cellular phosphorylation state (e.g. protein kinase A, protein
kinase C, cyclin dependent kinases) [49] phosphorylate ERs,Journal of Biomedicine and Biotechnology 3
thus aﬀecting ER functions, positively or negatively, such
as transcriptional activity, stability and nucleocytoplasmic
shuttling. Estradiol, cell cycle regulators, the enzymes PKA,
PKC, extracellular signals such as growth factors, cytokines
and neurotransmitters phosphorylate human ERα at serine
residues in the aminoterminal A/B domain (serine-104,
-106, -118, -154, -167). Phosphorylation sites at serines in
DBD, hinge region, and LBD (ser-236, -294, -305) have also
been identiﬁed. Phosphorylation at ser-118 in human ERα is
considered the consensus phosphorylation site for MAPKs
and potentiates the interaction with coactivators, while
phosphorylation of tyr-537 regulates ERα ligand binding. All
together, the ER-mediated signaling cascade, that is, ligand
binding, dimerization, DNA binding and interaction with
cellular cofactors, seems to be regulated by phosphorylation
of ERα (summarized in [50]). Studies on ERβ phospho-
rylation suggest that ser-106 and ser-94 phosphorylation
sites at the A/B domain modulate subnuclear mobility of
the receptor, the ERβ cellular levels, indicating thus that
these phosphorylated serine residues generate signals to
the ubiquitin proteasome pathway [51]. Phosphorylation
at ser-106 and ser-124 also enhance the interaction with
the coactivator SRC-1. Phosphorylation at ser-87 has been
identiﬁed as a regulator of ER-dependent gene expression
and growth of breast cancer cells [52]. Collectively, in the
presence of diverse physiological signals other than their
cognate ligand, the ERs may be activated, this accompanied
by an increased phosphorylation state, a pathway which
may be responsible for tissue-speciﬁc responses, especially in
cases where the concentration of these extracellular signals
(e.g., growth factors) is locally increased and estrogens are
too low.
2.2. Extranuclear Actions
2.2.1. Plasma Membrane ER. Studies demonstrating that
e s t r o g e n sc a nc a u s ee ﬀects too fast to be based on tran-
scriptional events led to the identiﬁcation of membrane
estrogen receptors responsible for non-genomic responses.
The estrogen receptor membrane form exists as a full-
length ER, as an isoform, or as a distinct receptor [53–55].
Membrane forms for both ERα and ERβ have been identiﬁed
[56]. The membrane localization of ER has been shown to be
mediated by the adaptor protein Shc and insulin-like growth
factor I receptor [57], while interaction with caveolin-1 and
palmitoylation occurring on a speciﬁc cysteine (C447) ER
residue also plays an important role in this localization
[57, 58].
Accumulated evidence strongly supports the importance
of plasma membrane estrogen receptors in a variety of
cells. GPR30, a G protein-coupled receptor (GPCR), binds
E2 with high aﬃnity and generates rapid eﬀects [58, 59],
including stimulating Ca2+ mobilization from intracellular
stores directly or via epidermal growth factor receptor
(EGFR) transactivation, c-fos expression, adenyl cyclase, and
cAMP mediated signaling and ERK-1/2 in a variety of cell
types [60].
Additional signal transduction pathways that are rapidly
responsive to E2 and originate from the membrane involve
the stimulation/inhibition (being dependent on the ERα or
ERβ subtype) of phosphoinositol-3hydroxy kinase (PI3K)
and the family of MAP kinases, such as extracellular-
regulated kinase (ERK), p38β isoform, as well as the c-Jun
N-terminal kinase (JNK) [61]. Indeed, E2 has been shown
to bind the transmembrane G-protein-coupled receptor
homolog GPR30 and to activate p44/42 MAPK through
transactivation of EGFR [62, 63]. Of note, the signaling
from the membrane can also extend to other intracellular
transcriptionfactorssuchasAP-1orNF-kB,resultingingene
repression or activation.
The non-genomic actions of estrogens seem to be
implicated in important functions such as cell growth, pro-
liferation, diﬀerentiation and apoptosis of various cell types
(endothelial, bone, neuronal cells, etc.). With regard to the
immune system, there are studies conﬁrming the presence of
the membrane ERα receptor in peripheral blood mononu-
clear cells (PBMCs), with estradiol inducing NO release and
calcium ﬂux through binding to this receptor. It is of interest
that the presence of tamoxifen did not antagonize this
eﬀect [64]. Moreover, estradiol acting in human monocytes
induced the rapid release of NO through membrane ERα
and/or ERβ [64]. Benten et al. [65] conﬁrmed the existence
of membrane ER in T-cells; according to their study, binding
of estradiol to membrane ER resulted in release of NO, an
eﬀect that was not abolished by the presence of tamoxifen.
2.2.2.MitochondrialER. Accumulatingevidencehasdemon-
strated that estrogens exert substantial eﬀects on mitochon-
drial function, some of these eﬀects being the following: (a)
estrogens are potent stabilizers of ATP production during
oxidative stress, while under basal conditions they show
little eﬀect on mitochondrial ATP production; (b) estrogens
prevent Ca++ inﬂux into mitochondria under high exci-
totoxic stimulation; (c) estrogens protect mitochondria by
preventing mitochondrial membrane potential collapse [66].
More importantly, E2—regulates the expression of mtDNA-
encoded respiratory chain subunits such as cytochrome
oxidase subunits I, II, III in various cell types/tissue [67–69].
SeverallaboratorieshavereportedthelocalizationofERα
and ERβ in mitochondria in various target cells and tissues
by a variety of techniques such as immunohistochemistry,
immunocytochemistry,andimmunoblotsusingawiderange
of antibodies. A number of studies have demonstrated the
presenceofERαinmitochondriaoffemaleratcerebralblood
vessels, MCF-7 cells, HepG2 cells, and the 2C12 murine
skeletal muscle cell line. Accumulating evidence supports
the presence of ERβ in the mitochondria in rabbit uterus
and ovary, in MCF-7 cells, in endothelial cells, in primary
neurons, primary cardiomyocytes, murine hippocampus
cell lines and human heart cells, in human lens epithelial
cells, human liver cancer HepG2 cells, osteosarcoma SaOS-
2, sperm, and periodontal ligament cells [66, 70]. The
localization of ERβ in mitochondria has also been veriﬁed
by proteomics. It should be noted that the wild type human
ERβ (known as ERβ1), and not the isoforms ERβ2t oE R β5,
is preferentially localized in the mitochondria [66, 70].
It is noteworthy that sequencesshowing partial similarity
toEREconsensussequencehavebeendetectedintheD-Loop4 Journal of Biomedicine and Biotechnology
region, the major regulatory region of the mitochondrial
genome[71,72].Severallinesofevidencehavedemonstrated
that ERα and ERβ exhibit speciﬁc binding to these mtEREs
[73], while the mitochondrial ERβ in immortalized human
breast epithelial cells (contain ERβ only) has been directly
associated with E2-induced expression of mtDNA-encoded
respiration chain subunits (COXI, COXII of complex IV and
ND1 of complex I) [74]. Collectively, the above data support
the hypothesis that the mitochondrial genome may be a
primary site of action of estrogens [71].
It is important to mention that an elevation of the
mitochondrial transmembrane potential and ATP depletion
has been observed in circulating lymphocytes of patients
with SLE [75, 76]. Moreover, lupus T cells overexpress genes
involved in mitochondrial electron transport [77], whereas a
borderline association at nt4917 of the ND2 gene (complex
I) and a signiﬁcant association of the variant at nt9055
in the ATP6 or F0F1-ATPase gene (complex V) have been
demonstratedinSLEpatients[78].Theabovedataimplythat
the estrogen-mitochondria crosstalk may be of importance
in the pathophysiology of SLE disease.
3. Estrogen Signalingandthe Regulation of
CytokinesinImmuneCells
Given the central role of estrogens in stimulating SLE
disease and because cytokines are substantially involved
in the pathogenesis of SLE, we herein provide evidence
elucidating the molecular basis of the interplay between
estrogen and cytokines in immune cells/organs known to
be of crucial importance in the control of the autoimmune
response.Becauseestrogensmediatetheireﬀectsviaestrogen
receptors (nuclear isoforms and/or membrane receptor),
studies have focused on the detection of the above receptors
in the immune cells (B cell, T cells, dendritic/macrophages,
monocytes) as well as in the immune organs (thymus) and
their possible role in autoimmunity [79].
T h et h y m u si sa ni m m u n eo r g a no fp r i m ei m p o r t a n c e
since it is well known that CD4+ and CD8+ T cell
development is a result of a complex process, starting with
the migration of progenitors from bone marrow to the
thymus and followed by positive and negative selection
processes that are critical for both ﬁnal maturation of T
cells and prevention of autoreactivity [80]. The loss of
thymus function, after ablation of a hyperplastic thymus
has been shown to contribute to the development of SLE
[81]. Moreover, the MRL/lpr strain (an SLE mouse model)
develops early in life autoimmune diseases characterized
by thymic atrophy [82]. Firstly, Stimson and Hunter [83]
demonstrated estrogen receptors in the human thymocytes.
Estrogen has been shown to lead to thymic atrophy through
various mechanisms including, among others, modulation
of the production of IL-7, an important regulator of T-
lymphopoiesis [84]. It is of import to bear in mind, the
presence of both ERα and ERβ is required to exert this
action, while in mice it has been demonstrated that ERα
needs to be expressed in both the hematopoietic and stromal
compartments of the thymus [85]; on the other hand, the
achievement of a full-sized thymus requires the presence of
ERα in stromal but not in thymic cells [85].
AdditionallytotheTcelldevelopment,estrogenhasbeen
shown to exert important eﬀects on T cell function through
ERs which have been identiﬁed in both CD4+ and CD8+ T
cells [86, 87] in a biphasic way. As already mentioned, that
SLE is characterized by a shift from the balance between Th-
1 and Th-2 subsets to Th-2 dominance. It is well known
that low doses of estrogen promote enhanced Th-1 responses
and increased cell-mediated immunity, while high doses of
estrogen lead instead to increased Th-2 responses [88, 89].
Of note, the enhancement of Th-1 responses to low-dose
estrogen required the presence of ERα,b u tn o tE R β [88].
The high estrogen levels that accompany pregnancy may
account for the stronger humoral responses and possibly
contribute to the ﬂares that some SLE patients experience
during pregnancy [90, 91]. This eﬀect of estrogens seems
to be achieved through direct alteration in the Th cytokine
proﬁle from a proinﬂammatory (IL-2, IFN-γ, TNF-a) to an
anti-inﬂammatorydirection(IL-4,IL-6,IL-10,TGF-β)[92].
Indeed, E2 as well as estrone and estriol have been shown to
stimulateIL-10inhumanCD4+cells[30,93,94],whiletheir
eﬀectonantigen-stimulatedsecretionofTNF-awasbiphasic,
with enhancement at low concentrations and inhibition at
high concentrations [93]. A stimulatory eﬀect of estriol on
IL-10 production, in contrast to the inhibitory eﬀect on
TNF-a, has also been revealed by Zang and coworkers [95].
Lambert et al. [96], in agreement with previous studies
[97,98],observed a signiﬁcantE2 induction of IL-4 secretion
by puriﬁed CD4+ T cells, an eﬀect mediated through ERα in
a classical ligand-dependent manner. IL-2, another cytokine
important for diﬀerentiation of T cell responses into Th-1
or Th-2 predominance, has been found to be suppressed by
highconcentrationsofestradiolinactivatedperipheralblood
T cells and CD4+ T cell lines [99].
A recent and highly interesting study by Xia et al. [100]
showed that estrogen replacement therapy increased the IL-
4 while decreasing IL-2 and IFN-γ secretion by T cells
isolated from surgically induced menopausal women, an
eﬀect which seems to be mediated mainly through ERα. An
ERα-mediated regulation of IL-2 and IFN-γ secretion is also
exhibited in splenic T cells [101]. Other cytokines, like IL-
12 which is a central stimulator of Th1 type cytokines [102],
as well as IL-1, are also inﬂuenced by estrogen action in
T cells, with divergent results [89, 103]. IL-17 is a novel
cytokine derived from T cells which has been shown to play
an important role in the Th-1/Th-2 balance [104] and has
recently been implicated in the pathogenesis of SLE [105].
A recent study showed that estradiol reduces the production
of IL-17 by upregulation of PD-1 (programmed death
1) expression within the Treg-cell compartment, an eﬀect
mediated through membrane ER [106, 107]. With respect
to IL-6, most studies, albeit conducted in PBMC or whole
blood cultures which include multiple cellular components,
demonstrated an inhibitory eﬀect of estrogen [108, 109].
Many studies have shown that estrogens regulate the
cytokine gene expression in diﬀerent cell types, via ER-
mediated pathways, either directly through EREs or indi-
rectly through interaction of ER with other transcriptionJournal of Biomedicine and Biotechnology 5
factors including NF-kB and AP-1 [43, 46]. EREs have been
recognized in the promoter of IFN-γ and IL-10 genes [110,
111]. It is of note that NF-kB response elements have also
been found in the promoter of several cytokine genes like
IL-6, IL-10, TNF-a IL-1β, IL-12, and IL-2 [112–114], while
there are cytokines, that can be transcriptionally regulated
through interaction of more than one transcription factor.
Indeed, IL-2 is tightly controlled by several transcription
factors that bind to the IL-2 promoter; these transcription
enhancers include NFAT, NF-kB, and AP-1, while there
is evidence that all binding sites on the IL-2 promoter
need to be occupied to ensure maximal transcritption
and production of IL-2 [114, 115]. Disturbances in the
transcriptionally active proteins, including NFAT (nuclear
factor of activated T cells), members of the AP-1 (c-Fos, c-
Jun), and NF-kB (c-rel, p50, p65) families, have been shown
to modulate cytokine gene expression in activated T cells
[112, 114, 116, 117]. Importantly, abnormal NF-kB signaling
characterized by decreased p65-RelA, increased c-rel and
reducedNF-kBDNAbindingactivity,associatedwithaltered
cytokine expression, has been recognized in T cells from SLE
patients [118–121]. Similarly, disturbances in AP-1-signaling
associated with alterations in c-fos protein expression and
AP-1 DNA binding activity has also been demonstrated in
T cells from SLE patients [122–124].
The question now arises: how the estrogen-estrogen
receptor pathway cross-react with NF-kB and/or AP-1
mediated signaling in lymphocytes to regulate cytokine gene
expression? Mechanistic studies on the direct interaction
between ER and NF-kB/AP-1 in immune cells, which is
presumed important in the control of estrogen-induced
immune responses and cytokine expression, are only sparse.
Zang et al. [95] were the ﬁrst to reveal that estriol altered
cytokine proﬁle of human normal T cells through inhibition
ofIkBadegradation[95];interestingly,thiseﬀectwasspeciﬁc
for NF-kB and not for other transcription factors like AP-1,
and was ER-mediated, since it was partially abolished in the
presence of tamoxifen [118, 119]. However, a recent study
hasdemonstratedthatE2,actingthroughERβ,coulddirectly
enhance NF-kB activity in human T cells, suggesting that
estrogen actions on NF-kB activity may depend on ER and
cell subtypes [125]. An enhanced transcriptional activity of
nuclear NF-kB p65 in macrophages from E2-treated mice
was also observed by Calippe et al. [126]; according to
their results, this enhanced NF-kB activation could be a
consequence of the reduced PI3K activity, as a result of
chronic exposure to estrogens, through direct or indirect
mechanisms, a hypothesis, however, which remains to be
elucidated.
Apart from T-cells, monocyte-derived dendritic cells are
substantially involved in the pathogenesis in SLE. Dysfunc-
tional dendritic cells in human SLE have been described.
In studies describing dysfunctional dendritic cells in human
SLE [127, 128], monocyte-derived dendritic cells from lupus
patients displayed an abnormal phenotype characterized
by accelerated diﬀerentiation, maturation, and secretion of
proinﬂammatory cytokines, suggesting that they are in a
preactivated state. Interesting eﬀects of estrogens on the
function as well as cytokine secretion by dendritic cells and
monocyte/macrophage have been demonstrated. Indeed,
Douin-Echinard et al. conﬁrmed that estrogens are required
to generate optimal numbers of fully functional dendritic
cells invitro,whiletheyinducesecretionofIL-6andIL-12;of
note, these eﬀects of E2 were dependent on ERα and not ERβ
[129]. E2 increased the B cell-stimulating IL-10 production
by monocytes [130]. Moreover, estrogen can enhance release
of IL-6, TNF-a and interleukin-1 (IL-1), from human
activated monocytes and/or macrophages, through modu-
lation of CD16 expression [131], although other pathways
not involving CD16, whether or not ER-mediated, have
previously been recognized [132–134]. At the same line, E2
was found to increase TNF-a, IL-6, and TGF-β secretion
by diﬀerentiated monocyte/macrophages [135]. It should
be noted that in regard to TNF-a and IL-1β, the existing
literature is at present inconsistent, with E2 either enhancing
or inhibiting their secretion by macrophages/monocytes
[30]. The divergent results concerning the estrogen eﬀect
on the expression of various cytokines would seem to be
attributable to diﬀerences in the cell type, in concentrations
of E2, in type of experiment (in vivo or in vitro)a sw e l la si n
duration (shortterm vs longterm) of E2 exposure. In support
of the latter, Calippe et al. [126] exhibited the fact that
chronic in vivo E2 administration promotes the expression
of IL-1β, IL-6, IL-12p40 by macrophages in response to
TLR4 activation, whilst short-term in vitro exposure in E2
decreased the expression of these inﬂammatory mediators.
All the above data strongly suggest that estrogens by
acting via their receptors and their crosstalk with other tran-
scription factors in immune cells and organs can modulate
immunological parameters and processes that have been
shown to be implicated in the pathogenesis of SLE.
4. Estrogen Signalingandthe Regulation
of Cytokinesin SLE
Numerous disorders of the immune system and abnormali-
ties in cytokine production have been described in patients
with SLE. Although there is much indirect evidence for
estrogen involvement in the lupus disease process, the direct
role of estrogen/estrogen receptor-mediated pathways in
regulating cytokine production in SLE patients has not as yet
been clearly deﬁned.
Pursuing the same line of research, Evans et al. [136]s e t
out to investigate the eﬀect of estrogen on spontaneous in
vitro apoptosis of PBMCs and T cells from women with SLE.
Although their data did not allow of any conclusion as to
which cell type was predominantly aﬀected by estrogen, nor
whether this was a direct or an indirect eﬀect, they never-
theless found that there was an estrogen-induced decrease in
apoptosiscombinedwithdecreasedTNF-aproductioninthe
presence of estrogens which could probably enable survival
of autoimmune cells in SLE patients. In the same study,
estrogen-induced production of other cytokines, like IFN-γ
or IL-1β, by PBMCs was not signiﬁcantly diﬀerent between
normal and SLE cell cultures.
However, the ﬁrst evidence for a molecular marker of
estrogen action in lupus patients was provided by Rider et6 Journal of Biomedicine and Biotechnology
al. [137], who suggested that estrogen-dependent changes
in lupus T cell calcineurin could alter proinﬂammatory
cytokine gene regulation and T-B cell interactions. Indeed,
application of RNase protection assays revealed increased
calcineurin expression in response to exogenous E2 in
cultured T cells from female lupus patients. Calcineurin is
known to stimulate dephosphorylation of substrates such
as nuclear factor of activated T cells (NFAT), resulting in
transactivation of target genes, including IL-2 [138, 139].
NFAT is a transcription factor that forms a complex with
Fos and Jun proteins in the nucleus of activated T cells.
Dephosphorylation by calcineurin translocates NFAT from
the cytoplasm to the nucleus, where it binds promoter
sequences and activates IL-2 transcription [140, 141]a sw e l l
as the CD40Ligand (CD40L) [142]. It should be mentioned
that CD40L plays a central role in pathogenic humoral
immune responses in SLE, providing contact-dependent Th
signals for B cell production of class-switched antibodies
[143–145].
Other transcriptional regulators that may be controlled
indirectly by calcineurin include the NF-kB (NF-kB)/Rel
proteins [146]. Rider et al., in seeking to delineate the
molecular mechanisms involved in estrogen control of cal-
cineurin [137], demonstrated that the estrogen-dependent
increase in intracellular calcineurin mRNA and its activity
is a direct eﬀect, mediated through ER.The same research
group established that 2-ﬂuoro-E2 exerted a signiﬁcant
increase in the amount of CD40L in peripheral blood T
cells from SLE patients, which was blocked by ICI 182780
(thus implying a ER-mediated action) [147]. Extending their
research ten years later, they demonstrated that by blocking
estrogen receptors in vivo by an estrogen selective receptor
downregulator (fulvestrant) in SLE premenopausal women,
they reduced signiﬁcantly the expression of calcineurin and
CD40L (CD154) mRNA in peripheral T cells [148].
In 2001, another research group [149] examined whether
changes in the cytokine milieu of SLE patients were asso-
ciated with serum sex hormone levels. According to their
results, SLE patients were characterized by higher levels of
endogenous serum E2; however, the observed abnormalities
in the cytokine milieu did not correlate with the abnormal
E2 serum levels, suggesting that increased E2 may induce
cytokine abnormalities only early in the disease, without
being implicated subsequently.
Given that SLE is considered to be a Th-2 cytokine-
driven disease, while pregnancy is also a condition in
which the cytokine environment is predominantly Th-
2 polarized, with an enhancement of antibody-mediated
immune responses, Doria et al. [150] decided to evaluate
levels of selected cytokines in the humoral immune response
during pregnancy in SLE patients. Notably, they found
high serum levels of IL-10 in SLE patients either before or
during pregnancy, thereby supporting the view that IL-10
overproduction in SLE is mainly constitutive rather than
modulated by estradiol. By contrast, in the same study IL-
6 serum levels in SLE women reﬂected the levels of E2
during the three trimesters of pregnancy, thus suggesting
its regulation by estrogen. Apart from the abovementioned
studies focused on direct eﬀects of E2 on the cytokine
production in SLE, a very recent study [151]i n v e s t i g a t e d
in PBMC of SLE patients the interaction among cytokines
and estradiol on the regulation of immune-response related
molecules; interestingly, using DNA microarrays analysis,
they failed to reveal any functional interaction between
estradiolandIFN-aontheexpressionofinterferon-inducible
genes in SLE.
A sex-related expression of the disease, similar to that
in man, is known to occur in several animal models of
autoimmune diseases. In many genetic based murine models
of lupus, including NZB/NZW F1 and MRL/lpr/lpr mice, the
females also develop more severe disease and higher titers of
autoantibodies at an earlier age [152, 153], while estrogen
supplementation is associated with worsening disease and
accelerated mortality. Supporting the direct implication of
estrogen in the development and the course of experimental
murine SLE, Sthoeger et al. [154] demonstrated therapeutic
eﬀects of tamoxifen (selective estrogen receptor modulator),
while three years later the same group [155]s u g g e s t e d
that these beneﬁcial eﬀects were associated with cytokine
modulations; indeed, treatment with tamoxifen restored the
levels of IL-2, IL-4, IFN-γ, TNF-a, and IL-1 to the normal
levels observed in control mice, thus implying an estrogen
receptor-mediated eﬀect. High levels of serum estrogen
have been associated with decreased IL-2 production in
NZB/NZW mice [156], while E2 treatment has been shown
to result in increased serum TNF-a and IL-6 levels following
LPSchallengeinnormalaswellasinMRL/lpr/lprmice;these
c h a n g e sw e r ea l s ob l o c k e db yt a m o x i f e n[ 157].
5.ERandSLE
In 1986, Weusten et al. [158], following the detection
of estrogen receptors in thymocytes and peripheral blood
monocytes of SLE patients, for the ﬁrst time proposed
the possibility of an ER implication in the pathogenesis of
SLE. At the same time, Kelly and Vertosick [159]s u g g e s t e d
the hypothesis of a potential role of ER as an autoantigen
in SLE; according to this hypothesis, the proposed target
of autoimmune attack, i.e. the estrogen receptor normally
resident in the nucleus, is physiologically more highly
activatedinwomen,whileautoantigenicityofERisenhanced
in SLE patients owing to an abnormality of estrogen
metabolism leading to metabolite-derivatives which favor
ligand occupancy of the receptor.
Thereafter, numerous studies have been carried out
speciﬁcallytoidentifyquantitativeandqualitativediﬀerences
in estrogen receptor(s) related to SLE disease, to Th-1 and
Th-2 cytokine expression as well as to clinical characteristics
like age onset, clinical symptoms, and disease activity, all,
however, with conﬂicting results. Indeed, Athreya et al.
[160]a sw e l la sS u e n a g ae ta l .[ 161], studying PBMC and
monocytes,didnotﬁndsigniﬁcantdiﬀerencesinthenumber
of estrogen receptors, nor in their binding aﬃnity, between
SLE patients and normal women, while Feng [162] revealed
diﬀerences related to the disease activity.
Since ERα splicing variants lacking speciﬁc functional
domains have been found in human estrogen-responsive
tissues and have been previously implicated in diseasesJournal of Biomedicine and Biotechnology 7
of estrogen-dependent tissues/cells, by aﬀecting estrogen
action, the expectation was that attention would be focused
on the identiﬁcation of possible diﬀerences in expression
of such ERα splicing variants by immune cells and their
correlation with SLE. Although Wilson et al. [163]s u g g e s t e d
that the presence of ER splice variant with deletion of exon 5
(DER5) in PBMC was causally related to SLE, experimental
results from our laboratory [164], in agreement with those
provided by Suenaga et al. [87], have shown that patients
aﬀected by SLE expressed in their peripheral blood T cells,
monocytes, and B-cell lines wild type ERα, DER5, and DER7
transcripts as did healthy individuals.
Since its ﬁrst identiﬁcation [32, 165], ERβ has continued
to be of particular interest as it is highly expressed in tissues
related to the immune system, potentially implying that
some of the immunomodulatory eﬀects of estrogens might
be mediated by this receptor form. Several studies have
demonstrated that monocytes and lymphocytes express both
ERα and ERβ [50, 164, 166], while quantitative diﬀerences
in the expression of ERα and ERβ mRNA have been
observed among cell populations such as T cells, B cells and
monocytes as assessed by Real Time Quantitative PCR (RQ-
PCR). Indeed, CD4+ T cells have been found to express
relatively high levels of ERα mRNA compared with ERβ
mRNA, whereas B cells expressed high levels of ERβ mRNA
and low levels of ERα mRNA [50, 166]. Additionally, in
the same study by Phiel et al. [166], CD8+ T cells and
monocytes expressed comparably low levels of both ERs.
Recently, proceeding in the same line of research, Xia et al.
found that both ERα and ERβ were expressed on T cells of
surgically induced menopausal women, with the expression
of ERα being higher than that of ERβ [100]. At mRNA level,
both ERα and ERβ are expressed by PBMC, as well as by
T cells isolated from lupus patients [137, 164]. However,
ar e c e n ts t u d y[ 167] conducted on PBMC of SLE patients
has demonstrated increased expression of ERα mRNA and
decreased expression of ERβ mRNA compared with PBMC
from normal controls. Interestingly, the highest expression
of ERα was observed in CD4+ and CD8+ T cells from
SLE patients, whereas ER mRNA expression by B cells from
SLE patients was decreased compared with normal B cells;
regarding ERβ, a signiﬁcant inverse correlation between ERβ
mRNA expression and the SLEDAI score was discerned. In
contrast, Rider et al. [168] found that the expression of ERα
or ERβ, as estimated by immunoblotting, was independent
of SLE disease activity, while both ERα and ERβ agonists
increased calcineurin and CD40L expression in SLE T cells
but not in normal T cells. It is of interest to note that,
although the amount of ERα appeared to be less in SLE T
cellsthanincontrolTcells,thisreceptorsubtypeparticipated
more than ERβ in the sensitivity of SLE T cells to estrogen.
These results, although in need of further clariﬁcation, are
indicative of a possible stronger inﬂuence of estrogen on T
cells, mediated mainly through ERα in SLE patients.
It must be mentioned here that mRNA expression is
not always correlated with expression at the protein level
or with the number of functional ERs simply because
posttranscriptional modiﬁcation of this receptor has been
shown to occur; this could oﬀer a possible explanation
for the conﬂicting results observed during the quantitative
evaluation of ERα and ERβ in immune cells [169].
Polymorphisms occur frequently throughout the human
genome and in some cases are known to alter either the
expression or the function of a gene product [170]. Several
studies have demonstrated the presence of a variety of
estrogen receptor polymorphisms and their association with
various diseases, among them SLE. Results from our labo-
ratory indicated that the estrogen receptor alpha codon 594
genotypemayinﬂuencethedevelopmentofSLEatayounger
age,aswellasaspeciﬁcdiseaseclinicalpattern,whileanother
two ERα polymorphisms in exon 1 (codon 10 and codon 87)
werenotassociatedwiththedisease[171].Otherstudieshave
shownthatPvuIIandXbaIpolymorphisms(intron1ofERα)
were associated with a milder form of SLE characterized by
skin manifestations, less organ damage as well as with early
onset of the disease [172, 173]. In the same line, a previous
study by Liu et al. [174] associated the PpXx genotype with a
higher frequency of skin rashes and arthritis in SLE patients,
while hematological abnormalities and hypertension were
more severe in patients with ppxx, and renal vasculitis and
interstitial injury in those with Ppxx genotype. Moreover,
the PpXx genotype of the ER gene was associated with the
susceptibility of SLE in the male but not in the female. A
very recent study conducted an interesting analysis of the
relationship between estrogen receptor polymorphisms and
the Th1 and Th2 cytokine expression in patients with SLE.
According to their results, Pvu II and XbaI polymorphisms
are associated with an alteration in the Th-1/Th-2 balance
in favor of Th-2, increasing the susceptibility to SLE. The
ﬁndings indicated that ERα gene polymorphisms could
inﬂuence the expression of IL-10, IL-4, IL-2 and IFN-γ
in SLE, with the Th-2 cell being predominant in patients
with PpXx and Ppxx genotypes [175]. Finally, another
recent study determined the impact of estrogen receptor null
genotypes on disease in NZM2410, and MRL/lpr mice, as a
method to deﬁne the role of estrogen receptor signaling in
lupus. Their data demonstrated a key role of ERα,b u tn o t
ERβ,inthedevelopmentoflupus-likediseaseinfemaleNZM
and MRL/lpr mice [176].
6. Conclusion
SLE is characterized by numerous immune system distur-
bances including alterations in cytokine regulation. Estro-
gens are known modulators of immune system functions,
inﬂuence cytokine production and are involved in the lupus
disease process. Accumulating evidence on the molecular
and cellular actions of estrogens via the estrogen receptor
subtypes ERα and ERβ adds to the depth of our understand-
ing of estrogen-estrogen receptor mediated signaling. Both
estrogen receptor proteins have been detected in immune
cells, while increasing information points to their possible
involvement in cytokine expression. However, in spite of
the clinical signiﬁcance of the estrogen-induced changes in
cytokineproductioninSLEdisease,manyofthekeyelements
in the underlying molecular mechanisms remain largely
unknown. Existing data show an estrogen receptor-mediated
eﬀect in the production of cytokines and other cytokine8 Journal of Biomedicine and Biotechnology
regulatory molecules (such as calcineurin and CD40L) in
humans and animal models of SLE disease. A possible
correlation of ER gene polymorphisms and of quantitative
and qualitative changes in the receptor proteins to cytokine
production and to disease aetiopathogenesis have also been
reported. Clearly, further elucidation of ER signaling in SLE
awaits characterization of the interactions of ER with the
many other intracellular molecules and/or its interplay with
other signaling pathways.
Recent evidence indicates a role of estrogens in mito-
chondrial function in immune cells along with cytokine reg-
ulation, while the existence of mitochondrial ER in human
cells has been associated with stimulation of mitochondrial
encoded enzymes. The above data, together with the recent
ﬁndingsthatSLEpatientsarecharacterizedbymitochondrial
dysfunction, suggest that novel pathways of the estrogen-
ER complex in mitochondria in immune cells may play a
key role in SLE. The use of gene and/or protein expression
proﬁling by microarray technology as well as the application
of other molecular biology techniques in elucidating the
underlying mechanisms will provide valuable information
about the “signature” of the ER-regulated cytokine proﬁle
that are highly likely to be helpful in the design of future
therapeutic strategies.
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